ObsEva SA (OBSEF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Mar 6, 2026
ObsEva Company Description
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health.
It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization.
The company was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA
| Country | Switzerland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Fabien de Ladonchamps |
Contact Details
Address: Chemin des Aulx, 12 Geneva, 1228 Switzerland | |
| Phone | 41 22 552 38 40 |
| Website | obseva.com |
Stock Details
| Ticker Symbol | OBSEF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CH1260041939 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Fabien Lefebvre de Ladonchamps | Chief Executive Officer and Director |
| Dr. Ernest Loumaye M.D., OB/GYN, Ph.D. | Co-Founder and Chairman |
| Delphine Renaud | Personal Assistant to the CSO and Head of Research & Development |